# A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

> **NCT02092922** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 154 (actual)

## Conditions studied

- Advanced Multiple Myeloma

## Interventions

- **DRUG:** Filanesib, KSP (Eg5) inhibitor; intravenous
- **DRUG:** Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

## Key facts

- **NCT ID:** NCT02092922
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-07
- **Final completion:** 2017-09-05
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092922, "A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02092922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*